BioLife Solutions, Inc. $BLFS Shares Acquired by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC boosted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 10.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 673,129 shares of the medical equipment provider’s stock after purchasing an additional 66,242 shares during the quarter. Stephens Investment Management Group LLC owned approximately 1.39% of BioLife Solutions worth $12,843,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. T. Rowe Price Investment Management Inc. grew its holdings in BioLife Solutions by 27.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 5,180,824 shares of the medical equipment provider’s stock worth $125,273,000 after acquiring an additional 1,113,972 shares in the last quarter. Capricorn Fund Managers Ltd bought a new position in BioLife Solutions during the 4th quarter worth approximately $9,153,000. Invesco Ltd. increased its holdings in shares of BioLife Solutions by 9.2% in the 4th quarter. Invesco Ltd. now owns 3,932,191 shares of the medical equipment provider’s stock valued at $95,080,000 after acquiring an additional 332,747 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of BioLife Solutions by 2,399.5% during the 2nd quarter. Qube Research & Technologies Ltd now owns 248,474 shares of the medical equipment provider’s stock valued at $5,352,000 after acquiring an additional 238,533 shares in the last quarter. Finally, Heights Point Management LP acquired a new position in BioLife Solutions in the fourth quarter worth $5,260,000. Institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

BLFS stock opened at $28.11 on Monday. BioLife Solutions, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $30.00. The company has a market capitalization of $1.37 billion, a P/E ratio of -351.33 and a beta of 1.94. The company has a 50-day simple moving average of $24.66 and a 200 day simple moving average of $23.10.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. The business had revenue of $27.50 million during the quarter, compared to analysts’ expectations of $25.66 million. BioLife Solutions had a negative net margin of 2.80% and a positive return on equity of 1.81%. Equities analysts anticipate that BioLife Solutions, Inc. will post 0.02 EPS for the current year.

Insiders Place Their Bets

In other news, major shareholder Casdin Partners Master Fund, L sold 650,000 shares of BioLife Solutions stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $23.70, for a total value of $15,405,000.00. Following the transaction, the insider owned 4,757,165 shares of the company’s stock, valued at $112,744,810.50. The trade was a 12.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Over the last three months, insiders have sold 1,200,000 shares of company stock valued at $28,125,000. 2.20% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Monday, April 20th. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 12th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $32.00.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.